The global oncology clinical trials market is projected to grow from approximately $14.95 billion in 2025 to $25.61 billion by 2035, representing a 5.53% compound annual growth rate from 2026 to 2035. ResearchAndMarkets.com said rising cancer incidence, pharmaceutical research spending and demand for advanced treatments are expanding development programs. Phase III trials account for more than 48.89% of the market, while interventional studies represent more than 71%. AstraZeneca, Merck & Co., Roche and Novartis together controlled approximately 35% of the oncology clinical trial pipeline in 2025. North America remained a leading region, accounting for more than 58% of radiation oncology studies in early 2024 and recording approximately 520,874 registered clinical studies by late 2024, including 68,453 cancer-related intervention trials. The report identifies artificial intelligence, precision medicine, biomarker-led research and international trial networks as important areas shaping future oncology development, while patient recruitment remains a major operational challenge.